One Test – Three Clinical Answers for Breast Cancer Patients

 

EndoPredict® is the only test that answers the following three important clinical questions…

  • Can chemotherapy be avoided? (individual risk at 10 years1)
  • What is the absolute benefit from chemotherapy? (individual chemotherapy benefit2)
  • Can endocrine therapy be stopped after 5 years? (individual risk up to 15 years3)

…to optimize treatment for breast cancer patients.

 

EndoPredict® is a prognostic and predictive gene expression assay for patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) early-stage breast cancer (node-negative (N0) or node-positive (N+) (1-3 nodes), pre- or postmenopausal). This second generation test combines a molecular score with tumor size and nodal status to provide more prognostic and predictive power than other tests.


Superior Prognostic Performance – Results you can Trust

 

  • Identifies the largest group of women with breast cancer at true low risk (4% to 5.8% recurrence in 10 years with 5 years of endocrine therapy alone)1,3,4,5
    • More than 70% of N0 patients
    • Up to 30% of N+ patients
  • Leads to a significant reduction in chemotherapy in clinical practice6,7,8
  • Inclusion of proliferation and hormone receptor related genes for accurate early and late risk assessment9
  • Validated in four prospective retrospective studies(with consistent study cohorts and constant cutoff)1,2,3,4,10,11 providing level 1 evidence
  • Offers a clear low or high risk category and individual absolute chemotherapy benefit
  • Provides fast result within 2 days by local testing

 

EndoPredict® provides a comprehensive individual result for each patient that allows for quick and confident decision-making.

 

 

 

 

 

Learn more about EndoPredict ®

References

  1. Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin Cancer Res. 2011; 17(18):6012-6020
  2. Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019; 176:377-386
  3. Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019;25:3865-3872
  4. Buus et al. Comparison of EndoPredict and EPclinWithOncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016 Jul 10; 108(11)
  5. Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018; 4(4):545-553
  6. Muller B.M. et al.: The EndoPredict Gene-Expression Assay in Clinical Practice – Performance and Impact on Clinical Decisions. PloSONE. 2013; 8(6): e68252
  7. Penault-Llorca et al.: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinicogenomic test on treatment decision making among patients with intermediate clinical risk. SABCS 2016
  8. Ettl J. et al.: Decision Impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker UPA/PAI-1. PLoSONE. 2017; 12(9): e0183917
  9. Dubsky P. et al.: The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancerpatients. BJC. 2013; 109, 2959–2964
  10. Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013; 24:640-647
  11. Martin M. et al.: Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− reast cancer patients: results from the GEICAM 9906 trial. BCR. 2014; 16:R38